Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are: * How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer? * Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival? * Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?

NCT Number	NCT06930807
Lead Sponsor	Peking University People's Hospital Collaborators: Peking University, Guangdong Provincial People's Hospital, Jiangsu Cancer Institute & Hospital, Shanghai Chest Hospital, Shandong Cancer Hospital and Institute, Shenzhen Third People's Hospital, Second Xiangya Hospital of Central South University, Shanghai Zhongshan Hospital, Peking University First Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Institute for Occupational Safety and Health (NIOSH/CDC)
Conditions	Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
Enrollment	1,000 participants
Start Date	2025-03-25
Primary Completion	2027-07-31 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-16